Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05300048 · ClinicalTrials.gov registry record · Phase 1
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
A Phase 1 study, sponsored by Faeth Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT05300048: Clinical Trial Phase 1 study, sponsored by Faeth Therapeutics.
NCT05300048 is a Phase 1 study that was terminated before completion, run by Faeth Therapeutics. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05300048, a Phase 1 study, was terminated before completion, sponsored by Faeth Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.
Primary Outcome
Incidence of related AEs
Interventions
- DRUG Nab paclitaxel
- DRUG Serabelisib
- OTHER Insulin Suppressing Diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 1 |
Why NCT05300048 stopped before completion
NCT05300048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 3 interventions - of which Nab paclitaxel is the first listed.
NCT05300048 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05300048 about?
NCT05300048 is a clinical study titled "Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations". This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.
What is the current status of trial NCT05300048?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2022-04-22. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT05300048?
The interventions under investigation include: Nab paclitaxel (DRUG), Serabelisib (DRUG), Insulin Suppressing Diet (OTHER).
Who is sponsoring clinical trial NCT05300048?
This trial is sponsored by Faeth Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05300048's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI